BTK and neoplasm: The anti-tumor effects of a second generation of ROR1 SMI, KAN0441571C (Table S1), was tested in in vitro and in vivo preclinical DLBCL models for the induction of tumor cell apoptosis as well as in combination with targeted therapeutics (BTK and BCL-2 inhibitors) with mechanisms of action other than ROR1 inhibitors.